Medicis Pharmaceutical Corporation (“Medicis,” the “Company,” or as used in the context of “we,” “us” or “our”), together with our wholly owned subsidiaries, is a leading independent specialty pharmaceutical company focusing primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the United States (“U.S.”) and Canada of products for the treatment of dermatological and aesthetic conditions. We believe that the U.S. market for dermatological pharmaceutical sales exceeds $6 billion annually. According to the American Society of Plastic Surgeons (“ASPS”), over 13.8 million cosmetic plastic surgery procedures (both surgical and minimally-invasive) were performed in the U.S. in 2011, an increase of five percent as compared to 2010.
![Medicis Pharmaceutical logo](https://files.capedge.com/DEF%2014A/0000950123-10-032223/p17193p1719300.gif)
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
521574808
Latest filings (excl ownership)
15-12B
Securities registration termination
26 Dec 12
15-12B
Securities registration termination
26 Dec 12
EFFECT
Notice of effectiveness
17 Dec 12
25-NSE
Exchange delisting
12 Dec 12
8-K
Entry into a Material Definitive Agreement
11 Dec 12
POS AM
Prospectus update (post-effective amendment)
11 Dec 12
POSASR
Automatic shelf registration (post-effective amendment)
11 Dec 12
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Dec 12
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Dec 12
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Dec 12
Latest ownership filings
11-K
Annual report of employee stock purchases
12 Jul 11
11-K/A
Annual report of employee stock purchases (amended)
12 Jul 11
11-K/A
Annual report of employee stock purchases (amended)
12 Jul 11
11-K/A
Annual report of employee stock purchases (amended)
12 Jul 11
NT 11-K
Notice of inability to timely file Form 11-K
30 Jun 11
11-K
Annual report of employee stock purchases
29 Jun 10
11-K
Annual report of employee stock purchases
29 Jun 09
11-K
Annual report of employee stock purchases
30 Jun 08
11-K
Annual report of employee stock purchases
29 Jun 07
11-K
Annual report of employee stock purchases
29 Jun 06
News
Stifel And Marex Announce Prime Brokerage Referral Partnership
28 May 24
Analysts Launch Coverage On Marex Group Stock: What You Need To Know
20 May 24
UBS Initiates Coverage On Marex Group with Buy Rating, Announces Price Target of $27
20 May 24
Citigroup Initiates Coverage On Marex Group with Buy Rating, Announces Price Target of $24
20 May 24
Barclays Initiates Coverage On Marex Group with Overweight Rating, Announces Price Target of $25
20 May 24
Press releases
Marex Group plc to Participate in Upcoming Piper Sandler Global Exchange & FinTech Conference
31 May 24
Stifel and Marex Announce Prime Brokerage Referral Partnership
28 May 24
Marex Group plc Announces Full Year 2023 Results and Q1 2024 Update
16 May 24
Marex Group plc to Report FY 2023 Results and Q1 2024 Update on May 16, 2024
13 May 24